Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 90-95

  Krishnan, Amrita ^a   Nademanee, Auayporn ^a   Fung, Henry C ^a   Raubitschek, Andrew A ^a   Molina, Arturo ^a   Yamauchi, Dave ^a   Rodriguez, Roberto ^a   Spielberger, Ricardo T ^a   Falk, Peter ^a   Palmer, Joycelynne M ^a   Forman, Stephen J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CARMUSTINE; CORTICOSTEROID; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPOXIA; KAPLAN MEIER METHOD; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PODOPHYLLOTOXIN; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 37849031802     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9248     Document Type: Article

References (34)

1. Rastetter W, Molina A, White CA: Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55:477-503, 2004
2. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
3. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
4. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
5. Pfreundschuh M, Trumper L, Osterborg A, et al: MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma - A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
6. Kewalramani T, Zelenetz AD, Hedrick EE, et al: High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis. Blood 96:2399-2404, 2000
7. Nademanee A, Molina A, Dagis A, et al: Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 1:46-54, 2000
8. Vose JM, Zhang MJ, Rowlings PA, et al: Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission - A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406-413, 2001
9. Josting A, Sieniawski M, Glossmann JP, et al: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 16:1359-1365, 2005
10. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
11. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
12. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
13. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
14. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
15. Laport GG: The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 12:59-65, 2006 (1 suppl 1)
16. Hunault-Berger M, Ifrah N, Solal-Celigny P, el: Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100:1141-1152, 2002
17. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
18. Lefrère F, Delmer A, Levy V, et al: Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica 89:1275-1276, 2004
19. Mangel J, Leitch HA, Connors JM, et al: Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol 15:283-290, 2004
20. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
21. Horning SJ, Negrin RS, Chao JC, et al: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558, 1994
22. Nademanee A, Molina A, O'Donnell MR, et al: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International index high and high-intermediate risk group. Blood 90:3844-3852, 1997
23. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
24. Vose JM, Bierman PJ, Enke C, et al: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23:461-467, 2005
25. Nademanee A, Forman S, Molina A, et al: A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896-2902, 2005
26. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 20:185-188, 2005
27. Schilder RJ, Emmanouilides C, Vo K, et al: Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL. J Clin Oncol 23:575s, 2005 (suppl; abstr 6562)
28. Zevalin (ibritumomab tiuxetan) prescribing information. Biogen Idec, San Diego, CA
29. Mills W, Chopra R, McMillan A, et al: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588-595, 1995
30. Jantunen E, Kuittinen T, Nousiainen T: BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 44:1151-1158, 2003
31. 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood 108:103a, 2006 (abstr 330)
32. Gopal AK, Gooley TA, Maloney DG, et al: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 102:2351-2357, 2003
33. Krishnan AY, Nademanee A, Raubitschek A, et al: A comparison of BEAM and yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to BEAM (ZBEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: Impact of radioimmunotherapy on transplant outcomes. Blood 108:865a, 2006 (abstr 3043)
34. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007